EAM
MDGL icon

Eagle Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Eagle Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$11.4M Buy
+32,396
New +$8.29M 0.06% 272

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Eagle Asset Management's MDGL Position: Q3 2024 in Review

Eagle Asset Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2024: 32,396 shares worth $11.4M. The stake represents 0.06% of the portfolio and ranks #272 among its holdings.

257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

  • Eagle Asset Management held 32,396 shares of Madrigal Pharmaceuticals worth $11.4M as of Q3 2024.
  • Madrigal Pharmaceuticals was a new Eagle Asset Management position in Q3 2024.
  • Madrigal Pharmaceuticals made up 0.06% of Eagle Asset Management's portfolio in Q3 2024, its #272 holding.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.